Zobrazeno 1 - 9
of 9
pro vyhledávání: '"George Papastratigakis"'
Autor:
Eliza Tsitoura, Eirini Vasarmidi, Eleni Bibaki, Athina Trachalaki, Chara Koutoulaki, George Papastratigakis, Sevasti Papadogiorgaki, George Chalepakis, Nikos Tzanakis, Katerina M. Antoniou
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-16 (2019)
Abstract Background Impaired mitochondria homeostasis and function are established hallmarks of aging and increasing evidence suggests a link with lung fibrosis. Mitochondria homeostasis may be also affected in alveolar macrophages (AMs) in idiopathi
Externí odkaz:
https://doaj.org/article/ffe638d991294f0f9ca0f3c76805b98e
Autor:
George A. Margaritopoulos, Athina Trachalaki, Athol U. Wells, Eirini Vasarmidi, Eleni Bibaki, George Papastratigakis, Stathis Detorakis, Nikos Tzanakis, Katerina M. Antoniou
Publikováno v:
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the
Externí odkaz:
https://doaj.org/article/c64c732659604ca0be6458d87bcda818
Autor:
Eleni Bibaki, Athina Trachalaki, George Chalepakis, Nikos Tzanakis, George Papastratigakis, Eliza Tsitoura, Sevasti Papadogiorgaki, Eirini Vasarmidi, Chara Koutoulaki, Katerina M. Antoniou
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-16 (2019)
Respiratory Research
Respiratory Research
Background Impaired mitochondria homeostasis and function are established hallmarks of aging and increasing evidence suggests a link with lung fibrosis. Mitochondria homeostasis may be also affected in alveolar macrophages (AMs) in idiopathic pulmona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e7827c592fb599a053fe2e9dc74536
https://doi.org/10.1186/s12931-019-1196-6
https://doi.org/10.1186/s12931-019-1196-6
Autor:
Dimitrios Kouvidakis, Alexandra Papaioannou, Vasileia Nyktari, Georgios Stefanakis, George Papastratigakis, Eleni Diamantaki, Periklis Vasilos
Publikováno v:
Signa Vitae. 17:8
Introduction: Despite advances in treatment strategies, patients with severe burns rapidly develop complex metabolic changes and multiorgan failure, compromising survival. Severe burns are the ones complicated by major trauma or inspiratory injury, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd94783d88bf3550e6f5cdb579f78b68
https://doi.org/10.22514/sv.2021.155
https://doi.org/10.22514/sv.2021.155
Autor:
Alexandra Papaioannou, Georgios Stefanakis, Eleni Diamantaki, Vasileia Nyktari, George Papastratigakis, Nikolaos Tserlikakis, Periklis Vasilos, Emmanouela Koutoulaki
Publikováno v:
Signa Vitae. 17:39
Introducton: Survival post-severe burn has increased significantly, and prognosis is not limited to survival or functionality, but extends to ensuring a pain-free quality of life. Pain management is one of the most crucial challenges in the care of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47f99e0fd024d12d205128f44095ae45
https://doi.org/10.22514/sv.2021.184
https://doi.org/10.22514/sv.2021.184
Autor:
Evangelia Stamataki, George Meletis, George Margaritopoulos, Katerina M. Antoniou, Athina Trachalaki, Eleni Bibaki, George Papastratigakis, Nikolaos Tzanakis, Eirini Vasarmidi
Publikováno v:
Idiopathic interstitial pneumonias.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08ab5c9dd706e80d74cde031e5f8d81c
https://doi.org/10.1183/13993003.congress-2018.pa4787
https://doi.org/10.1183/13993003.congress-2018.pa4787
Autor:
Athina Trachalaki, George Papastratigakis, Eleni Bibaki, Katerina M. Antoniou, Nikolaos Tzanakis, Eliza Tsitoura, George Margaritopoulos, Eirini Vasarmidi
Publikováno v:
Idiopathic interstitial pneumonias.
NOD-like receptors(NLRs) are key cytosolic components of the innate immune system. Upon activation they form the inflammasomes, that mediate the maturation and cleavage of IL-1b, a pro-inflammatory cytokine with fibrotic properties. NLRP3 activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1860647707ab31eb68d4e2a9af48067
https://doi.org/10.1183/13993003.congress-2018.pa4813
https://doi.org/10.1183/13993003.congress-2018.pa4813
Autor:
Athol U. Wells, Eirini Vasarmidi, George Margaritopoulos, Athina Trachalaki, Nikos Tzanakis, Stathis Detorakis, Eleni Bibaki, George Papastratigakis, Katerina M. Antoniou
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-7 (2018)
Background Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the restrict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7df4366d548dca15d0875d9a5e3226a
https://pubmed.ncbi.nlm.nih.gov/30470213
https://pubmed.ncbi.nlm.nih.gov/30470213
Autor:
Eirini Vasarmidi, Despoina Moraitaki, Konstantinos Karagiannis, Evaggelia Stamataki, Nikolaos Tzanakis, Eleni Bibaki, Athina Trachalaki, George Papastratigakis, Stelios Michelakis, Katerina M. Antoniou
Publikováno v:
Diffuse Parenchymal Lung Disease.
Introduction: Pirfenidone is an anti-fibrotic agent that slows down disease progression in patients with IPF. Notably, it reduces the risk of all-cause mortality by 48%in this group of patients. Aim: To evaluate the efficacy of Pirfenidone treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e4ab99a1684af78f321185d361108f1
https://doi.org/10.1183/1393003.congress-2017.oa3397
https://doi.org/10.1183/1393003.congress-2017.oa3397